Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2017 Mar 12

PMID 28282903

Citations 5

Authors

Mailin Li

Pasquale Cascino

Simone Ummarino

Annalisa Di Ruscio

Affiliations

Soon will be listed here.

Abstract

The burst of reprogramming technology in recent years has revolutionized the field of stem cell biology, offering new opportunities for personalized, regenerative therapies. The direct reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) has provided an invaluable tool to study and model a wide range of human diseases. Here, we review the transforming potential of such a strategy in research and in therapies applicable to the hematology field.

Citing Articles

Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.

Dhanjal D, Singh R, Sharma V, Nepovimova E, Adam V, Kuca K Curr Med Chem. 2023; 31(13):1646-1690.

PMID: 37138422 DOI: 10.2174/0929867330666230503144619.

The PARP Way to Epigenetic Changes.

Ummarino S, Hausman C, Di Ruscio A Genes (Basel). 2021; 12(3).

PMID: 33804735 PMC: 8003872. DOI: 10.3390/genes12030446.

Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics.

Tuasha N, Petros B Scientifica (Cairo). 2020; 2020:4736091.

PMID: 33133722 PMC: 7568790. DOI: 10.1155/2020/4736091.

Conditional reprogramming: Modeling urological cancer and translation to clinics.

Liu W, Ju L, Cheng S, Wang G, Qian K, Liu X Clin Transl Med. 2020; 10(2):e95.

PMID: 32508060 PMC: 7403683. DOI: 10.1002/ctm2.95.

Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside.

Focosi D, Amabile G Cells. 2017; 7(1).

PMID: 29280988 PMC: 5789275. DOI: 10.3390/cells7010002.

References

Woll P, Grzywacz B, Tian X, Marcus R, Knorr D, Verneris M . Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009; 113(24):6094-101. PMC: 2699231. DOI: 10.1182/blood-2008-06-165225. View

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

Urnov F, Miller J, Lee Y, Beausejour C, Rock J, Augustus S . Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005; 435(7042):646-51. DOI: 10.1038/nature03556. View

Lengerke C, Daley G . Autologous blood cell therapies from pluripotent stem cells. Blood Rev. 2009; 24(1):27-37. PMC: 2913579. DOI: 10.1016/j.blre.2009.10.001. View

Amabile G, Welner R, Nombela-Arrieta C, DAlise A, Di Ruscio A, Ebralidze A . In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood. 2012; 121(8):1255-64. PMC: 3701251. DOI: 10.1182/blood-2012-06-434407. View

Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger R, Bernstein I . Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010; 16(2):232-6. PMC: 2819359. DOI: 10.1038/nm.2080. View

Wong K, Yeap W, Tai J, Ong S, Dang T, Wong S . The three human monocyte subsets: implications for health and disease. Immunol Res. 2012; 53(1-3):41-57. DOI: 10.1007/s12026-012-8297-3. View

Grompe M, DAndrea A . Fanconi anemia and DNA repair. Hum Mol Genet. 2001; 10(20):2253-9. DOI: 10.1093/hmg/10.20.2253. View

Daley G . From embryos to embryoid bodies: generating blood from embryonic stem cells. Ann N Y Acad Sci. 2003; 996:122-31. DOI: 10.1111/j.1749-6632.2003.tb03240.x. View

10.

Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D . Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013; 12(1):114-26. DOI: 10.1016/j.stem.2012.11.002. View

11.

Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen A . Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008; 26(7):795-7. PMC: 6334647. DOI: 10.1038/nbt1418. View

12.

Hanna J, Wernig M, Markoulaki S, Sun C, Meissner A, Cassady J . Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318(5858):1920-3. DOI: 10.1126/science.1152092. View

13.

Lowry W, Richter L, Yachechko R, Pyle A, Tchieu J, Sridharan R . Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. 2008; 105(8):2883-8. PMC: 2268554. DOI: 10.1073/pnas.0711983105. View

14.

Evans M, Kaufman M . Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292(5819):154-6. DOI: 10.1038/292154a0. View

15.

Yanagimachi M, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y . Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 2013; 8(4):e59243. PMC: 3616072. DOI: 10.1371/journal.pone.0059243. View

16.

Carpenter L, Malladi R, Yang C, French A, Pilkington K, Forsey R . Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood. 2011; 117(15):4008-11. DOI: 10.1182/blood-2010-08-299941. View

17.

Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R . HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014; 371(4):339-48. PMC: 5965695. DOI: 10.1056/NEJMsa1311707. View

18.

Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S . Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008; 322(5903):949-53. DOI: 10.1126/science.1164270. View

19.

Gump J, Dowdy S . TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med. 2007; 13(10):443-8. DOI: 10.1016/j.molmed.2007.08.002. View

20.

Linette G, Stadtmauer E, Maus M, Rapoport A, Levine B, Emery L . Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6):863-71. PMC: 3743463. DOI: 10.1182/blood-2013-03-490565. View